{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T04:56:35Z","timestamp":1696395395256},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1007\/s11864-004-0027-1","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T08:40:14Z","timestamp":1183020014000},"page":"367-375","source":"Crossref","is-referenced-by-count":8,"title":["Osteoclast-targeted therapy for prostate cancer"],"prefix":"10.1007","volume":"5","author":[{"given":"Matthew R.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"27_CR1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-1-4615-3398-6_18","volume":"324","author":"M Harada","year":"1992","unstructured":"Harada M, Iida M, Yamaguchi M, Shida K: Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol 1992, 324:173\u2013182.","journal-title":"Adv Exp Med Biol"},{"key":"27_CR2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000474311","volume":"24","author":"NW Clarke","year":"1993","unstructured":"Clarke NW, McClure J, George NJ: Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 1993, 24:286\u2013290.","journal-title":"Eur Urol"},{"key":"27_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1464-410X.1991.tb15260.x","volume":"68","author":"NW Clarke","year":"1991","unstructured":"Clarke NW, McClure J, George NJ: Morphometric evi-dence for bone resorption and replacement in pros-tate cancer. Br J Urol 1991, 68:74\u201380.","journal-title":"Br J Urol"},{"key":"27_CR4","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","volume":"15","author":"P Garnero","year":"2000","unstructured":"Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD: Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmeno-pausal women: the OFELY study. J Bone Miner Res 2000, 15:1526\u20131536.","journal-title":"J Bone Miner Res"},{"key":"27_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0022-5347(05)67149-2","volume":"164","author":"A Berruti","year":"2000","unstructured":"Berruti A, Dogliotti L, Bitossi R, et al.: Incidence of skel-etal complications in patients with bone metastatic prostate cancer and hormone refractory disease: pre-dictive role of bone resorption and formation mark-ers evaluated at baseline. J Urol 2000, 164:1248\u20131253.","journal-title":"J Urol"},{"key":"27_CR6","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1210\/jc.86.9.4133","volume":"86","author":"RM Murray","year":"2001","unstructured":"Murray RM, Grill V, Crinis N, et al.: Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 2001, 86:4133\u20134138.","journal-title":"J Clin Endocrinol Metab"},{"key":"27_CR7","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"345","author":"MR Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Zietman AL, et al.: Pamidr-onate to prevent bone loss in men receiving gonadot-ropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001, 345:948\u2013955.","journal-title":"N Engl J Med"},{"key":"27_CR8","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1097\/01.ju.0000097351.48848.1f","volume":"170","author":"CS Higano","year":"2003","unstructured":"Higano CS: Management of bone loss in men with pros-tate cancer. J Urol 2003, 170:S59-S63;discussion S64.","journal-title":"J Urol"},{"key":"27_CR9","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","volume":"80","author":"MJ Rogers","year":"1997","unstructured":"Rogers MJ, Watts DJ, Russell RG: Overview of bisphos-phonates. Cancer 1997, 80:1652\u20131660.","journal-title":"Cancer"},{"key":"27_CR10","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001, 7:377 -387.","journal-title":"Cancer J"},{"key":"27_CR11","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S, et al.: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21:3150\u20133157.","journal-title":"J Clin Oncol"},{"key":"27_CR12","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carci-noma. J Natl Cancer Inst 2002, 94:1458 -1468. This pivotal randomized controlled trial demonstrated that zoledronic acid decreases risk of skeletal complications in men with hormone-refractory prostate cancer and bone metastases. It provides the first proof of principle for osteo-clast- targeted therapy in men with metastatic prostate cancer and established a new standard for treatment.","journal-title":"J Natl Cancer Inst"},{"key":"27_CR13","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","volume":"21","author":"EJ Small","year":"2003","unstructured":"Small EJ, Smith MR, Seaman JJ, et al.: Combined analy-sis of two multicenter, randomized, placebo-con-trolled studies of pamidronate disodium for the palliation of bone pain in men with metastatic pros-tate cancer. J Clin Oncol 2003, 21:4277\u20134284.","journal-title":"J Clin Oncol"},{"key":"27_CR14","unstructured":"Ernst D, Tannock I, Venner P, et al.: Randomized pla-cebo controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Can-ada Clinical Trials Group study.\n                           Proc Am Soc Clin Oncol 2002, Abstract 705:177a."},{"key":"27_CR15","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","volume":"95","author":"DP Dearnaley","year":"2003","unstructured":"Dearnaley DP, Sydes MR, Mason MD, et al.: A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003, 95:1300\u20131311. This randomized controlled trial evaluated the efficacy of clo-dronate in men with hormone-sensitive metastatic prostate cancer. Bone progression-free survival and overall survival did not differ significantly between the groups, but the trend toward better outcomes sets the stage for CALGB 90202\u2014a larger study of zoledronic acid in similar patient population.","journal-title":"J Natl Cancer Inst"},{"key":"27_CR16","doi-asserted-by":"crossref","unstructured":"Mason MD, Collaborators MP: Development of bone metastases from prostate cancer: first results of the MRC PR04 trial (ISCRTN 61384873) [abstract].\n                           Proc Am Soc Clin Oncol 2004, 4511.","DOI":"10.1200\/jco.2004.22.90140.4511"},{"key":"27_CR17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","volume":"92","author":"TH Diamond","year":"2001","unstructured":"Diamond TH, Winters J, Smith A, et al.: The antios-teoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, pla-cebo- controlled crossover study. Cancer 2001, 92:1444\u20131450.","journal-title":"Cancer"},{"key":"27_CR18","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason D, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing ADT for nonmetastatic pros-tate cancer. J Urol 2003, 169:2008\u20132012. This multicentered randomized controlled trial demonstrated that zoledronic acid increases bone mineral density in men receiving ADT. The results of this study make zoledronic acid an attractive option to prevent treatment-related osteoporosis.","journal-title":"J Urol"},{"key":"27_CR19","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","volume":"91","author":"MR Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Fallon MA, et al.: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001, 91:2238\u20132245.","journal-title":"Cancer"},{"key":"27_CR20","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1210\/jc.84.10.3431","volume":"84","author":"JP Bilezikian","year":"1999","unstructured":"Bilezikian JP: Osteoporosis in men. J Clin Endocrinol Metab 1999, 84:3431\u20133434.","journal-title":"J Clin Endocrinol Metab"},{"key":"27_CR21","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1056\/NEJM199709043371003","volume":"337","author":"B Dawson-Hughes","year":"1997","unstructured":"Dawson-Hughes B, Harris SS, Krall EA, Dallal GE: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337:670\u2013676.","journal-title":"N Engl J Med"},{"key":"27_CR22","first-page":"442","volume":"58","author":"E Giovannucci","year":"1998","unstructured":"Giovannucci E, Rimm EB, Wolk A, et al.: Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998, 58:442\u2013447.","journal-title":"Cancer Res"},{"key":"27_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1023\/A:1008823601897","volume":"9","author":"JM Chan","year":"1998","unstructured":"Chan JM, Giovannucci E, Andersson SO, et al.: Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998, 9:559\u2013566.","journal-title":"Cancer Causes Control"},{"key":"27_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1023\/A:1008835903714","volume":"9","author":"E Giovannucci","year":"1998","unstructured":"Giovannucci E: Dietary influences of 1,25(OH)2 vita-min D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998, 9:567\u2013582.","journal-title":"Cancer Causes Control"},{"key":"27_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL: Osteoclast differenti-ation and activation. Nature 2003, 423:337\u2013342.","journal-title":"Nature"},{"key":"27_CR26","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS, et al.: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmeno-pausal women. J Bone Miner Res 2004, 19:1059\u20131066.","journal-title":"J Bone Miner Res"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0027-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-004-0027-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0027-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0027-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T13:12:21Z","timestamp":1652620341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-004-0027-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["27"],"URL":"https:\/\/doi.org\/10.1007\/s11864-004-0027-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}